Sigumir is a cartilage-derived bioregulatory peptide that promotes regeneration of articular cartilage, tendons, and ligaments. It restores structural gene expression and reduces inflammation, aiding recovery from arthritis and joint degeneration.
Sigumir
Also known as: A-6 Cartilage & Connective Tissue Bioregulator
Overview
Benefits
- Cartilage regeneration
- Reduced joint inflammation
- Collagen protection
- Enhanced musculoskeletal healing
- Connective tissue resilience
Consider This Peptide If You Want To
- Support cartilage repair and reduce joint pain
- Strengthen connective tissue
Dosage & Administration
Dosage Guidelines
Recommended Dosage
• Amount:20 mg
• Frequency:daily
• Duration:4 weeks
• Rest Period:16 weeks
• Time of Day:morning
• Ingestion:oral
Best taken with meals to enhance gastrointestinal absorption. Monitor joint function improvements.
Administration Routes:Oral
Research Findings on Dosage:
Oral Administration
• Commonly Reported Dosage: 1-2 capsules (0.215 g each) twice daily (this equates to 20-40 mg of peptide complex A-4)
• Duration: 30 days per cycle, repeat every 4--6 months or as clinically indicated
• Administration Notes: Best taken with meals to enhance gastrointestinal absorption
Mechanism of Action
Mechanism of Action
How this peptide works in the body
Cartilage Matrix Gene Reactivation
Sigumir induces histone acetylation (H3K27ac, H4K8ac) in chondrocytes, which opens chromatin at loci encoding structural proteins like COL2A1 (type II collagen), ACAN (aggrecan), and COMP. This promotes re-synthesis of the extracellular matrix, improving cartilage resilience and hydration. The peptide may also stimulate SOX9, a master transcription factor critical for chondrogenic lineage maintenance.
Inflammation Modulation in Joint Microenvironment
Sigumir inhibits NF-κB signaling in synoviocytes and macrophages, reducing production of pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6. This reduces synovial membrane thickening and leukocyte infiltration, creating a more regenerative microenvironment. It concurrently upregulates anti-inflammatory mediators like IL-10.
Inhibition of Catabolic Enzymes and Cartilage Breakdown
The peptide downregulates matrix metalloproteinases (MMP-1, MMP-13) and ADAMTS enzymes that degrade collagen and proteoglycans. It enhances TIMP-3 expression, protecting structural matrix proteins from enzymatic cleavage and preserving cartilage architecture under inflammatory stress.
Support of Mesenchymal Stem Cell (MSC) Chondrogenesis
Sigumir activates TGF-β and Wnt signaling pathways in mesenchymal progenitor cells, enhancing chondrogenic differentiation and tissue integration. It boosts expression of RUNX2 and SOX9, coordinating early proliferation with late-stage matrix deposition. This contributes to cartilage thickening and surface integrity restoration.
Collagen Cross-linking and ECM Remodeling
The peptide increases lysyl oxidase (LOX) activity, enhancing cross-linking of collagen fibrils in the cartilage matrix. It also supports ECM turnover by balancing fibronectin and decorin synthesis, improving tissue tensile strength and elasticity.
Consider Stacking With
- Thymalin
- Epitalon
- Chonluten
- Ventfort
- Glandokort
Side Effects & Cautions
Common Side Effects
- None reported
Cautions
- Use with caution in autoimmune arthritis
- Not a replacement for orthopedic therapy
Rare Side Effects
- Mild digestive upset (rare)
Research & References
Research Highlights
Khavinson et al., 2014: Reported significant improvements in joint mobility and pain scores in osteoarthritis patients using Sigumir.
Trofimova et al., 2013: Observed upregulation of cartilage matrix gene expression and reduced inflammatory cytokines in treated subjects.
Morozov et al., 2012: Demonstrated inhibition of catabolic enzymes and enhanced ECM integrity in degenerative joint models.
Khavinson & Linkova, 2016: Identified epigenetic activation of chondrocyte-specific gene networks by Sigumir peptide fragments.
References
Khavinson V, et al. "Peptide regulation of joint tissue in osteoarthritis models." Int J Mol Sci. 2014.
Trofimova SV, et al. "Chondroprotective effects of tissue-specific peptides in degenerative diseases." J Clin Gerontology. 2013.
Morozov VG, et al. "Modulation of extracellular matrix remodeling by cartilage peptides." Peptides. 2012.
Khavinson V, Linkova N. "Gene reactivation in connective tissue with bioregulatory peptides." Biogerontology. 2016.